The Age, Gamma-Glutamyl Transpeptidase and Platelet Index: A Novel Noninvasive Model for Predicting Hepatocellular Carcinoma in Patients with Hepatitis B Virus-Related Liver Cirrhosis

References

• Su GL, Altayar O, O’Shea R, et al. AGA clinical practice guideline on systemic therapy for hepatocellular carcinoma. Gastroenterology. 2022;162(3):920–934. doi:10.1053/j.gastro.2021.12.276
   PubMed Web of Science ®Google Scholar
• Zhang CH, Cheng Y, Zhang S, Fan J, Gao Q. Changing epidemiology of hepatocellular carcinoma in Asia. Liver Int. 2022;42:2029–2041. doi:10.1111/liv.15251
   PubMed Web of Science ®Google Scholar
• Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, El-Serag HB. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology. 2017;153(4):996–1005 e1001. doi:10.1053/j.gastro.2017.06.012
   PubMed Web of Science ®Google Scholar
• Kim BS, Seo YS, Kim YS, et al. Reduced risk of hepatocellular carcinoma by achieving a subcirrhotic liver stiffness through antiviral agents in hepatitis B virus-related advanced fibrosis or cirrhosis. J Gastroenterol Hepatol. 2018;33(2):503–510. doi:10.1111/jgh.13854
   PubMed Web of Science ®Google Scholar
• Kim SU, Seo YS, Lee HA, et al. Hepatocellular carcinoma risk steadily persists over time despite long-term antiviral therapy for hepatitis b: a multicenter study. Cancer Epidemiol Biomarkers Prev. 2020;29(4):832–837. doi:10.1158/1055-9965.EPI-19-0614
   PubMed Web of Science ®Google Scholar
• Zhu DM, Xie J, Ye CY, Qian MY, Xue Y. Risk of hepatocellular carcinoma remains high in patients with HBV-related decompensated cirrhosis and long-term antiviral therapy. Can J Gastroenterol Hepatol. 2020;2020:8871024. doi:10.1155/2020/8871024
   PubMed Web of Science ®Google Scholar
• Nakai M, Yamamoto Y, Baba M, et al. Prediction of hepatocellular carcinoma using age and liver stiffness on transient elastography after hepatitis C virus eradication. Sci Rep. 2022;12(1):1449. doi:10.1038/s41598-022-05492-5
   PubMed Web of Science ®Google Scholar
• Ioannou GN, Beste LA, Green PK, et al. Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores. Gastroenterology. 2019;157(5):1264–1278 e1264. doi:10.1053/j.gastro.2019.07.033
   PubMed Web of Science ®Google Scholar
• Huang TH, Lin MT, Wang JH, et al. Clinical and novel application of FibroScan, FIB-4 and aspartate aminotransferase-to-platelet ratio index in liver fibrosis evaluation in patients with hepatocellular carcinoma and their roles in oesophageal variceal prediction. Int J Clin Pract. 2021;75(4):e13945. doi:10.1111/ijcp.13945
   PubMed Web of Science ®Google Scholar
• Younes R, Caviglia GP, Govaere O, et al. Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. J Hepatol. 2021;75(4):786–794. doi:10.1016/j.jhep.2021.05.008
   PubMed Web of Science ®Google Scholar
• Kawaguchi T, Ide T, Amano K, et al. Enhanced liver fibrosis score as a predictive marker for hepatocellular carcinoma development after hepatitis C virus eradication. Mol Clin Oncol. 2021;15(4):215. doi:10.3892/mco.2021.2377
   PubMedGoogle Scholar
• Tamaki N, Kurosaki M, Yasui Y, et al. Change in fibrosis 4 index as predictor of high risk of incident hepatocellular carcinoma after eradication of hepatitis c virus. Clin Infect Dis. 2021;73(9):e3349–e3354. doi:10.1093/cid/ciaa1307
   PubMed Web of Science ®Google Scholar
• Ji F, Zhou R, Wang W, et al. High post-treatment alpha-fetoprotein levels and aspartate aminotransferase-to-platelet ratio index predict hepatocellular carcinoma in hepatitis c virus decompensated cirrhotic patients with sustained virological response after antiviral therapy. J Interferon Cytokine Res. 2017;37(8):362–368. doi:10.1089/jir.2017.0040
   PubMed Web of Science ®Google Scholar
• Kim JH, Kim JW, Seo JW, Choe WH, Kwon SY. Noninvasive tests for fibrosis predict 5-year mortality and hepatocellular carcinoma in patients with chronic hepatitis B. J Clin Gastroenterol. 2016;50(10):882–888. doi:10.1097/MCG.0000000000000574
   PubMed Web of Science ®Google Scholar
• Lee HW, Cho YY, Lee H, et al. Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B. Hepatol Int. 2021;15(5):1083–1092. doi:10.1007/s12072-021-10234-2
   PubMed Web of Science ®Google Scholar
• Tseng TC, Choi J, Nguyen MH, et al. One-year Fibrosis-4 index helps identify minimal HCC risk in non-cirrhotic chronic hepatitis B patients with antiviral treatment. Hepatol Int. 2021;15(1):105–113. doi:10.1007/s12072-020-10124-z
   PubMed Web of Science ®Google Scholar
• Demir M, Grunewald F, Lang S, et al. Elevated liver fibrosis index FIB-4 is not reliable for HCC risk stratification in predominantly non-Asian CHB patients. Medicine. 2016;95(38):e4602. doi:10.1097/MD.0000000000004602
   PubMed Web of Science ®Google Scholar
• Nartey YA, Awuku YA, Agyei-Nkansah A, et al. Ambulatory end-stage liver disease in Ghana; patient profile and utility of alpha fetoprotein and aspartate aminotransferase: platelet ratio index. BMC Gastroenterol. 2020;20(1):428. doi:10.1186/s12876-020-01581-9
   PubMed Web of Science ®Google Scholar
• Hann HW, Wan S, Lai Y, et al. Aspartate aminotransferase to platelet ratio index as a prospective predictor of hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection. J Gastroenterol Hepatol. 2015;30(1):131–138. doi:10.1111/jgh.12664
   PubMed Web of Science ®Google Scholar
• Nishikawa H, Nishijima N, Enomoto H, et al. Comparison of FIB-4 index and aspartate aminotransferase to platelet ratio index on carcinogenesis in chronic hepatitis B treated with entecavir. J Cancer. 2017;8(2):152–161. doi:10.7150/jca.16523
   PubMed Web of Science ®Google Scholar
• Paik N, Sinn DH, Lee JH, et al. Non-invasive tests for liver disease severity and the hepatocellular carcinoma risk in chronic hepatitis B patients with low-level viremia. Liver Int. 2018;38(1):68–75. doi:10.1111/liv.13489
   PubMed Web of Science ®Google Scholar
• Zhu YF, Tan YF, Xu X, et al. Gamma-glutamyl transpeptidase-to-platelet ratio and the fibrosis-4 index in predicting hepatitis B virus-related hepatocellular carcinoma development in elderly chronic hepatitis B patients in China: a single-center retrospective study. Medicine. 2019;98(50):e18319. doi:10.1097/MD.0000000000018319
   PubMed Web of Science ®Google Scholar
• Jia JD, Hou JL, Wei L, Zhuang H. [Highlights of the guidelines of prevention and treatment for chronic hepatitis B (2019 version)]. Zhonghua Gan Zang Bing Za Zhi. 2020;28(1):21–23. Chinese. doi:10.3760/cma.j.issn.1007-3418.2020.01.006
   PubMedGoogle Scholar
• Department of Medical Administration, NH, Health Commission of the People’s Republic of, C. [Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)]. Zhonghua Gan Zang Bing Za Zhi. 2020;28(2):112–128. Chinese. doi:10.3760/cma.j.issn.1007-3418.2020.02.004
   PubMedGoogle Scholar
• Bengtsson B, Widman L, Wahlin S, Stal P, Bjorkstrom NK, Hagstrom H. The risk of hepatocellular carcinoma in cirrhosis differs by etiology, age and sex: a Swedish nationwide population-based cohort study. United European Gastroenterol J. 2022;10:465–476. doi:10.1002/ueg2.12238
   PubMed Web of Science ®Google Scholar
• Duberg AS, Lybeck C, Falt A, Montgomery S, Aleman S. Chronic hepatitis B virus infection and the risk of hepatocellular carcinoma by age and country of origin in people living in Sweden: a national register study. Hepatol Commun. 2022;6:2418–2430. doi:10.1002/hep4.1974
   PubMed Web of Science ®Google Scholar
• Kim M, Lee Y, Yoon JS, et al. The FIB-4 index is a useful predictor for the development of hepatocellular carcinoma in patients with coexisting nonalcoholic fatty liver disease and chronic hepatitis B. Cancers. 2021;13(10). doi:10.3390/cancers13102301
   Web of Science ®Google Scholar
• Liang LY, Lee HW, Wong VW, et al. Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B. Clin Mol Hepatol. 2021;27(3):499–509. doi:10.3350/cmh.2020.0333
   PubMed Web of Science ®Google Scholar
• Huang CF, Jang TY, Jun DW, et al. On-treatment gamma-glutamyl transferase predicts the development of hepatocellular carcinoma in chronic hepatitis B patients. Liver Int. 2022;42(1):59–68. doi:10.1111/liv.15085
   PubMed Web of Science ®Google Scholar